Home / News / Company News / Amoytop's Quality Center awarded CNAS certificate

Amoytop's Quality Center awarded CNAS certificate

Views: 0     Author: Site Editor     Publish Time: 2023-09-15      Origin: Site


facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
whatsapp sharing button
sharethis sharing button

Recently, Amoytop’s Quality Center was awarded the certificate issued by China National Accreditation Service for Conformity Assessment (CNAS) (Certificate number: CNAS L4479).

This is the first time that the drug testing laboratories of the Quality Center has been recognized by CNAS after the relocation of a new site, and it is also the first time for the Quality Center to pass the inspection after the upgrade of CNAS regulations, marking that Amoytop has the nationally and internationally recognized management level and testing ability in drug testing.

The China National Accreditation for Conformity Assessment (CNAS) is an authority determined by the State Administration for Market Regulation to engage in accreditation and evaluation of conformity assessment bodies such as certification bodies, laboratories, inspection bodies, validation and verification bodies, and is responsible for the operation of the national accreditation system for conformity assessment bodies.

The CNAS certificate has fully proved Amoytop's superiority in the field of drug testing. Amoytop always adheres to the concept of "Quality by Design (QbD)" and strictly follows the regulations of the National Medical Products Administration (NMPA) and the requirements of Good Manufacturing Practice (GMP). With reference to the relevant regulations of the World Health Organization (WHO), the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), the European Medicines Agency (EMA), and the Food and Drug Administration (FDA), a strict, efficient and continuously improved quality management system has been established.

This system ensures the safety, effectiveness and well controlled quality of drugs, and effectively protects the vital interests of patients. At present, the company's testing scope covers 4 testing areas, involving nearly 100 testing items approved, which can effectively ensure the company's product quality, and also provide customers with professional and personalized third-party testing report services.

In the future, Amoytop will continue to pursue excellence, improve the quality management system, and promote a higher level of drug testing technology, laying a solid foundation for the company's long-term development.

Specialized in R&D and production of recombinant protein drugs, and committed to providing better solutions for viral hepatitis, malignant tumor and immunotherapy etc..
Leave a Message
Get In Touch